New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
07:03 EDTMNKMallinckrodt reports Q3 adjusted EPS $1.20, consensus 87c
Reports Q3 revenue $653.1M consensus $611.9M
News For MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
06:14 EDTMNKBellerophon expands license agreement with Mallinckrodt for INOpule development
Bellerophon (BLPH) has expanded its license agreement with INO Therapeutics, a division of Mallinckrodt (MNK), allowing Bellerophon to develop INOpulse for the treatment of three additional cardiopulmonary diseases, including chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with pulmonary edema from high altitude sickness. Bellerophon's existing license with INO Therapeutics covers the development of INOpulse for pulmonary arterial hypertension, pulmonary hypertension associated with COPD and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Terms of the expanded license agreement include a 5% royalty on net sales for the three additional indications.
July 27, 2015
17:58 EDTMNKMallinckrodt to sell CMDS business to Guerbet for $270M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use